ALX Oncology Holdings Inc. Common Stock (ALXO)
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that target immune evasion mechanisms in cancer. The company’s lead program aims to improve outcomes for patients by restoring the immune system’s ability to fight tumors. Headquartered in the United States, ALX Oncology is dedicated to advancing research and development in immuno-oncology.
Company News
Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.
The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.
HP's stock rallied after BofA swings to bullish from bearish, while McCormick's stock leads the S&P 500's losers after a sales miss.
Investors are cheering the immuno-oncology company's latest clinical trial results.